Following a Delayed Launch, Bristol Myers Squibb’s Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights
Spherix’s new launch tracking service will further monitor details of Zeposia’s uptake over 18 months and benchmark key metrics against historical launches, including Genentech’s Ocrevus and Novartis’ Mayzent EXTON, Pa., September 16, 2020 /PRNewswire/ — With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, oral DMT class share has […]
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains EXTON, Pa., September 15, 2020 / PRNewswire / – In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. In each wave, approximately 250 specialists share […]
Recent, Positive Efficacy Data for Janssen’s Stelara in Refractory Crohn’s Disease Significantly Boost Patient Share for the IL-12/23 Inhibitor, According to Spherix Global Insights
Physician-reported prescribing patterns for Stelara in Crohn’s disease have begun to mirror the favorable impact that the VARSITY clinical trial data continue to have for Takeda’s Entyvio in ulcerative colitis EXTON, Pa., September 9, 2020 /PRNewswire/ — According to the latest report published as part of Spherix’s RealTime Dynamix™: Inflammatory Bowel Disease US service, gastroenterologists (n=100) continue to […]
SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights
The SGLT2 inhibitor class, specifically Janssen’s Invokana (promoted by Relypsa in nephrology), is gaining momentum with nephrologists as potential DKD indications loom for AstraZeneca’s Farxiga and Boehringer Ingelheim/Eli Lilly’s Jardiance EXTON, Pa., / September 8, 2020 / PRNewswire – With the increasing prevalence of diabetes across the United States, concern about diabetic kidney disease (DKD) […]
Nephrologists Point to Profound Unmet Need for New Agents to Treat Glomerular Diseases Such as IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), and Lupus Nephritis
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and Calliditas’ NEFECON to offer new options for patients suffering with these conditions EXTON, Pa., / August 31, 2020 / PRNewswire – Glomerular diseases pose some of the greatest challenges to nephrologists: they are progressive and […]
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies for the second year in a row, continues to invest in its areas of deep expertise: dermatology, gastroenterology, nephrology, neurology, and rheumatology EXTON, Pa., August 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix […]
The US Hyperkalemia Market Remains a Battle Ground Between AstraZeneca’s LOKELMA (zirconium sodium cyclosilicate) and Vifor/Relypsa’s VELTASSA (patiromer FOS)
According to a recently published report by Spherix Global Insights, after rapid trial of Lokelma in hyperkalemia, treatment patterns are beginning to settle in – with each competitor starting to dominate in certain patient types EXTON, Pa., / August 24, 2020 / PRNewswire – Despite the recent emergence of new therapeutic options to treat hyperkalemia, […]
Dermatologists Are Extremely Satisfied with Sanofi/Regeneron’s Dupixent in Atopic Dermatitis, Though the Brand Leaves Certain Patient Segments Untapped: Will JAK Inhibitors Be the One to Fill the Gap?
US and EU5 dermatologists are excited about the potential approvals of Eli Lilly’s Olumiant (baricitinib), Pfizer’s abrocitinib, and AbbVie’s Rinvoq (upadacitinib), though challenges likely lie ahead for the future atopic dermatitis JAKs EXTON, Pa., August 20, 2020 /PRNewswire/ — Atopic dermatitis (AD), commonly referred to as eczema, affects millions of patients across the globe. In […]
Recent Label Revisions Related to Constipation and Hypertension Generate Minimal Drag on the Decision to Prescribe Amgen/Novartis’ Aimovig as a Preventive Treatment for Migraine
The recent launch of Teva’s Ajovy autoinjector appears to be paying dividends, while market access and autoinjector preference are no longer distinct points of differentiation for Eli Lilly’s Emgality, according to Spherix Global Insights’ most recent patient chart audit EXTON, Pa., August 18, 2020/PRNewswire/ — Distinctive prescribing patterns and drivers of brand selection among the […]
Primary Care Providers Report High Prevalence of Chronic Kidney Disease and Categorize It as One of the Most Challenging Conditions to Manage
An independent audit conducted by Spherix Global Insights analyzed the charts of more than 1,000 patients with moderate to severe kidney disease who had not yet been referred to a nephrologist EXTON, Pa., August 13, 2020 /PRNewswire/ — According to the National Kidney Foundation, one in three Americans over the age of 20 (a striking […]
